"...inflammation market is over $100 billion.."
Spot on Itsa, the references by the company to the wider inflammation market beyond DMD has been growing stronger in recent times.
Their scientific advisory board and the BoD has some serious heavyweights.....and 40% stock held by major holders does provide some defence against predators BUT....
I can see liquidity event way before we become a major global player...probs straight after Phase IIb in Europe.
I do like your $2 target
Ann: Positive preliminary results from ATL1102 DMD Phase II trial, page-129
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.5¢ | $94.55K | 900.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 694053 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 167385 | 4 |
View Market Depth
| Last trade - 14.59pm 02/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |